Use of neurokinin receptor antagonists to treat androgen-dependent diseases
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
May 27, 2003
Grant Date -
May 15, 2003
app pub date -
May 7, 2002
filing date -
May 8, 2001
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK.sub.1), neurokinin-2 (NK.sub.2) and neurokinin-3 (NK.sub.3) receptors, (b) antagonists of NK.sub.1 and NK.sub.2 receptors, (c) antagonists of NK.sub.2 and NK.sub.3 receptors, (d) antagonists of NK.sub.1 and NK.sub.3 receptors, (e) antagonists of NK.sub.1 receptors, and (f) antagonists of NK.sub.2 to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully